Marseille

• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano … Ended
  2023-506314-51-00 9 2020-07-31 Stage IIIB or IIIC or IIID melanoma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto … Ended
  2023-506312-41-00 9 2020-07-30 PD-1 refractory melanoma
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors Ended
  2024-512135-80-00 4 2020-07-13 Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarco
• Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended
  2022-502116-36-00 5 2020-07-10 Incurable/Non-metastatic Hepatocellular Carcinoma
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r … Ended
  2024-518265-10-01 1 2020-06-03 Relapse/ refractory acute Leukemia
• Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syn … Ended
  2024-512448-41-00 5 2020-04-01 Bronchiolitis Obliterans Syndrome in Patients post Single or post Doub
• Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Ended
  2024-513984-22-00 4 2020-03-17 Patients with metastatic GIST
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended
  2024-511427-34-00 5 2020-02-20 idiopathic pulmonary fibrosis
• Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Ended
  2023-509866-39-00 3 2020-02-14 Locally advanced/metastatic breast or non-small cell lung cancer
• A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended
  2023-507904-30-00 3 2020-01-27 solid tumors
• Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLC Ended
  2024-517429-24-00 7 2020-01-09 Non-small-cell lung cancer
• MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended
  2024-514873-22-00 5 2019-10-16 Unresectable locally advanced and/or metastatic soft-tissue sarcoma
• Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study) Ended
  2024-515532-72-00 4 2019-10-08 non small cell lung cancer
• Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended
  2023-503956-29-00 5 2019-08-26 Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient M
• A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended
  2024-516201-23-00 4 2019-08-26 Lung Cancer, NSCLC
• The Late Presenter Treatment Optimisation Study (LAPTOP) Ended
  2023-505167-36-00 5 2019-08-05 Patients who present late on during their acquisition of the HIV-1 (Hu
• A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment f … Ended
  2024-514705-62-00 5 2019-07-08 Recurrent rectal cancer after local excision
• Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 Ended
  2024-511885-35-00 5 2019-07-03 macular telangiectasia type 1
• A study to assess different investigational drugs for the treatment if hidradenitis suppurativa Ended
  2023-509296-16-00 4 2019-06-17 Moderate to severe hidradenitis suppurativa
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC

Showing 1,441–1,464 of 1,518 trials